What Is CXCL9? Its Role in Immunity and Disease

CXCL9 is a small signaling protein, a chemokine, that the immune system produces mainly in response to interferon-gamma (IFN-γ). Its core job is to attract specific immune cells, particularly certain T cells and natural killer cells, toward sites of infection, inflammation, or tumor growth. That function makes CXCL9 a central player in how the body fights cancer, clears infections, and, when regulation breaks down, drives autoimmune damage. Research over the past decade has also placed CXCL9 at the center of aging biology, immunotherapy response, and transplant monitoring, giving this single molecule an outsized footprint across modern medicine.

How CXCL9 Gets Made

CXCL9 is not sitting around waiting to be used. Cells produce it on demand, almost exclusively when IFN-γ tells them to. The molecular cascade involves a transcription factor called STAT1, which is essential for switching on the CXCL9 gene. In brain immune cells called microglia, for example, deleting STAT1 completely abolishes the ability of IFN-γ to trigger CXCL9 production.¹ In skin cells called keratinocytes, the same STAT1 pathway works alongside another signaling molecule, NF-κB, to drive CXCL9 output.²

Which cell types make CXCL9 matters for how the immune response unfolds. In the central nervous system, microglia (the brain’s resident immune cells) are the primary producers, while a related chemokine called CXCL10 is made by both microglia and astrocytes.³ In tumors, macrophages are often the dominant source. This cell-specific production shapes where immune cells end up congregating and how effectively they attack their targets.

The CXCR3 Receptor and Its Three Chemokine Partners

CXCL9 does not work alone. It belongs to a trio of chemokines, along with CXCL10 and CXCL11, that all bind the same receptor on immune cells: CXCR3. These three chemokines are best known for drawing activated T helper 1 cells, cytotoxic T cells, and natural killer cells to sites of inflammation.⁴ Think of CXCR3 as a docking station and the three chemokines as ships that pull in to the same port but carry different cargo instructions.

Despite sharing a receptor, these three chemokines are not interchangeable. Studies of how each one activates CXCR3 reveal clear differences. CXCL10 is a strong activator of the main CXCR3A splice variant, triggering robust downstream signaling. CXCL9, by contrast, produces only modest activation of one key signaling pathway (ERK1/2 phosphorylation) through CXCR3A.⁵ The receptor itself also has splice variants, and each variant responds differently to the three ligands. The result is a layered system where different tissues can fine-tune which immune signals get amplified depending on which CXCR3 variant they express.

At a structural level, CXCL9 and CXCL10 rely heavily on the tail end of the CXCR3 receptor and a protein called beta-arrestin1 to trigger cell movement. CXCL11, meanwhile, depends more on a different part of the receptor’s interior.⁶ These structural distinctions help explain why the three chemokines, though superficially redundant, produce different biological outcomes.

CXCL9 in Cancer and Why Oncologists Care

The connection between CXCL9 and anti-tumor immunity has become one of the most active areas of cancer immunology research. The logic is straightforward: for checkpoint immunotherapy drugs like anti-PD-1 and anti-CTLA-4 to work, cytotoxic T cells need to physically enter the tumor. CXCL9 is one of the signals that pulls those T cells in.

In mouse cancer models, both CXCL9 and CXCL10 are sharply upregulated after combined PD-1 and CTLA-4 blockade. When researchers blocked the CXCR3 receptor so T cells could no longer follow the CXCL9/CXCL10 gradient, CD8+ T cell infiltration into tumors collapsed, and the immunotherapy stopped working. Macrophages turned out to be the main cells producing CXCL9 in both the mouse models and in patients receiving immunotherapy; depleting those macrophages wiped out the T cell response.⁷

Separate work confirmed CXCL9’s unique importance by showing that a protein called LIF, which many tumors produce, suppresses CXCL9 in tumor-associated macrophages. When LIF was neutralized, CXCL9 levels rose and CD8+ T cells flooded into tumors. Critically, in mice lacking the CXCL9 gene entirely, blocking LIF had no anti-tumor effect, confirming that CXCL9 was the key downstream mediator.⁸

There is also a flip side. When immune cells cannot respond to CXCL9 and CXCL10 gradients, tumors in colorectal cancer models show reduced infiltration by both killer T cells and regulatory T cells, leading to increased tumor burden.⁹ The immune system needs these chemokine highways to mount any organized response inside a tumor, whether that response is attack or regulation.

Stopping Blood Vessel Growth in Tumors

CXCL9 does not just recruit immune cells. It also fights tumors by choking off their blood supply through anti-angiogenic activity, and it does this through a mechanism that is largely independent of its receptor CXCR3.

Research on bone biology found that CXCL9 physically binds to VEGF, the major growth factor that stimulates new blood vessel formation, and prevents VEGF from attaching to the surface of endothelial cells. Blocking CXCR3 with a drug did not rescue the blood vessel suppression, confirming that CXCL9’s anti-angiogenic activity works through direct VEGF sequestration rather than through its usual receptor.¹⁰

A fragment of the CXCL9 protein, specifically the tail end spanning amino acids 74 to 103, has strong affinity for sugar-like molecules called glycosaminoglycans on cell surfaces. This fragment alone significantly reduced blood vessel growth driven by multiple growth factors, including VEGF, EGF, and FGF-2, both in lab dishes and in living animals.¹¹ A shorter fragment with weaker affinity for those sugar molecules showed no anti-angiogenic activity, suggesting the tail region’s grip on glycosaminoglycans is essential.

Predicting Who Will Respond to Immunotherapy

Because CXCL9 is so tightly linked to whether T cells can get inside tumors, it has drawn attention as a potential biomarker to predict which patients will benefit from checkpoint immunotherapy. In ovarian cancer mouse models that were resistant to anti-PD-L1 therapy on their own, engineering tumors to overexpress CXCL9 was enough to enable a successful immunotherapy response. Adding anti-PD-L1 on top of CXCL9 overexpression worked even better, significantly extending survival compared to either approach alone.¹²

Researchers have also explored whether measuring CXCL9 expression, combined with a handful of other immune genes, could predict immunotherapy outcomes across multiple cancer types. A panel combining CXCL9 with IFN-γ and GBP5 expression was independently associated with anti-PD-L1 response in bladder cancer patients and showed predictive value when validated across immunotherapy datasets from different tumor types.¹³ The idea is not that CXCL9 alone tells you everything, but that it is a strong signal of whether the tumor microenvironment is “hot” enough for immunotherapy to gain traction.

When CXCL9 Turns Against You: Autoimmune Disease

The same T-cell-recruiting power that makes CXCL9 useful against tumors can cause serious harm when the immune system mistakenly targets the body’s own tissues. Vitiligo, the skin condition that causes patches of depigmentation, is one of the clearest examples. In vitiligo, the IFN-γ/CXCL9/CXCL10/CXCR3 signaling axis recruits CD8+ T cells into the epidermis, where those T cells kill melanocytes, the pigment-producing cells.¹⁴ In mouse models, CXCL9 and CXCL10 expression in the skin correlates strongly with disease activity, making them potential markers for tracking whether vitiligo is progressing or stable.¹⁵

Rheumatoid arthritis tells a similar story in a different tissue. Microarray analysis of the joint lining in rheumatoid arthritis patients found that CXCL9, along with CXCL10, STAT1, and IRF1, was significantly upregulated compared to the joint tissue of osteoarthritis patients.¹⁶ CXCL9 draws T cells into the joint lining, fueling the chronic inflammation that destroys cartilage and bone. In animal models of rheumatoid arthritis, blocking CXCL9 reduces the influx of inflammatory cells into the joints.¹⁷

The paradox, then, is that CXCL9 is both a molecule you want more of in cancer and a molecule you want less of in autoimmune disease. Any therapeutic strategy targeting this axis needs to navigate that tension carefully.

Monitoring Transplant Rejection

CXCL9’s role as a “danger signal” has found a practical application in transplant medicine. When a transplanted organ or bone marrow graft starts being rejected, the recipient’s immune system ramps up IFN-γ production, which in turn drives CXCL9 levels upward. In children undergoing bone marrow transplant for bone marrow failure, CXCL9 levels in the blood at the time of fever were dramatically higher in patients experiencing graft rejection compared to febrile children who were not rejecting. The difference was stark: a median of about 1,744 pg/mL in the rejection group versus 45 pg/mL in controls. A threshold of roughly 322 pg/mL identified graft rejection with perfect sensitivity and specificity in that cohort.¹⁸ That is a small study, and larger validation is needed, but it illustrates the potential for CXCL9 to serve as an early warning system when rejection is beginning.

CXCL9 and Aging

One of the more surprising findings about CXCL9 comes from the study of aging itself. A deep-learning analysis of blood inflammatory markers in a large cohort identified CXCL9 as the single strongest contributor to a metric the researchers called “iAge,” an inflammatory clock of aging. Higher iAge tracked with frailty, multiple chronic diseases, weakened immune function, and cardiovascular aging. CXCL9 specifically was linked to adverse cardiac remodeling and poor vascular function.¹⁹

The connection was not merely correlational. When researchers silenced CXCL9 in aging endothelial cells from both humans and mice, those cells recovered function, reversed markers of cellular senescence, and lost the stiffness phenotype characteristic of aged arteries.²⁰ This positions CXCL9 not just as a passive marker of aging-related inflammation but as an active participant in the vascular decline that accompanies getting older. Intriguingly, centenarians, who represent exceptional longevity, also showed a distinct iAge profile, suggesting the inflammatory clock captures something meaningful about biological versus chronological age.

A Potential Tool Against Severe Infections

The CXCL9(74-103) peptide fragment, the same tail region with anti-angiogenic properties, has also been tested in infectious disease models. In mice infected with a betacoronavirus, treatment with this fragment reduced the accumulation of inflammatory cells, especially neutrophils, in the lung’s airspaces and improved several measures of lung function. In a SARS-CoV-2 mouse model, the peptide improved clinical symptoms, reduced lung damage, and lowered the amount of virus in the lungs.²¹

The mechanism here is different from CXCL9’s classic immune-recruiting role. The peptide fragment competes with inflammatory chemokines for binding to glycosaminoglycans on blood vessel walls. By bumping active chemokines off those docking sites, the fragment disrupts the chemical gradient that draws excessive numbers of neutrophils and other inflammatory cells into damaged tissue.²² In severe infections like COVID-19, much of the organ damage comes from runaway inflammation rather than the virus itself, so dampening that over-recruitment could be protective.

Engineering Better Versions for Therapy

If you want to use CXCL9 as a cancer drug, you face a practical problem: the body rapidly chews it up. An enzyme called DPP-4 clips the front end of CXCL9 and CXCL10, crippling their ability to activate CXCR3. Recent work has addressed this by adding a single amino acid, glutamine, to the front of CXCL9 fused to an antibody fragment (Fc). This engineered molecule remained fully active at the CXCR3 receptor but resisted DPP-4 degradation, and preclinical tests in cancer models showed significant therapeutic potential.²³

Meanwhile, the anti-inflammatory CXCL9(74-103) peptide represents a different therapeutic angle: rather than boosting T cell recruitment as the engineered Fc fusion does, the peptide dampens excessive inflammation by competing for glycosaminoglycan binding. The same molecule yielding two opposing therapeutic strategies, depending on which piece you use, underscores how much functional complexity is packed into a single chemokine.

Measuring CXCL9 in the Clinic

As interest in CXCL9 as a biomarker has grown, so has the need for accurate, standardized blood tests. Two recently developed assays illustrate the state of the art. One uses electrochemiluminescence technology and achieves a lower limit of quantification of about 1.64 pg/mL in human serum, making it sensitive enough to detect even low background levels of circulating CXCL9.²⁴ Another, a fully automated immunoassay, showed strong precision across both serum and plasma samples with no cross-reactivity from other chemokines and no interference from common blood contaminants like bilirubin or hemoglobin.²⁵

These assays matter because many of the clinical applications described above, transplant monitoring, immunotherapy prediction, inflammatory aging assessment, hinge on being able to measure CXCL9 reliably and precisely in routine blood draws. As the assays become more widely available, CXCL9 testing could become a practical clinical tool rather than a research curiosity, joining a small but growing set of chemokine markers that bridge the gap between laboratory immunology and bedside decision-making.